Cost Utility of Transcatheter Aortic Valve Replacement: Sapien 3 Versus CoreValve Evolut R
- 22 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , 475-482
Abstract
Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for severe aortic stenosis. Previous studies compare clinical outcomes of leading TAVR valves, but there is no evidence of cost-utility comparison, leaving a clinical information gap when selecting valves. Here we share a cost-utility analysis comparing the Sapien 3 (S3) (Edwards Lifesciences, Irvine, CA) and CoreValve Evolut R (ER) (Medtronic, Dublin, IR) across five clinical endpoints. Utility scores from patient surveys and clinical outcomes from the literature were used to estimate quality-adjusted life years (QALYs) associated with successful procedure and postoperative complications for S3 and ER. A decision tree was constructed with rollback analysis to highlight the more cost-effective strategy. An incremental cost-utility ratio (ICUR) analysis was performed with a willingness to pay at $50,000. Deterministic and probabilistic sensitivity analyses were performed to validate robustness of results and account for uncertainty. S3 was found to be more costly ($68,377 vs. $66,072), but more effective (1.87 vs. 1.66) compared with ER. An ICUR of 11,288.12 favored S3, making it the more cost-effective option with a moderate confidence of 73.68% in Monte Carlo analysis. Cost-utility analysis can be used to aid in healthcare economics decision-making when selecting between comparable technologies used for TAVR procedures.Keywords
This publication has 34 references indexed in Scilit:
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsNew England Journal of Medicine, 2016
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisNew England Journal of Medicine, 2014
- Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve ReplacementJAMA, 2014
- The cost effectiveness of acellular dermal matrix in expander–implant immediate breast reconstructionJournal of Plastic, Reconstructive & Aesthetic Surgery, 2014
- A Comparison of Acellular Dermal Matrix to Autologous Dermal Flaps in Single-Stage, Implant-Based Immediate Breast ReconstructionPlastic and Reconstructive Surgery, 2013
- A Comparison of Free Autologous Breast Reconstruction with and without the Use of Laser-Assisted Indocyanine Green AngiographyPlastic and Reconstructive Surgery, 2013
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementBJOG: An International Journal of Obstetrics & Gynaecology, 2013
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- The Use of Disease-Specific Outcome Measures in Cost-Utility AnalysisPharmacoEconomics, 2007
- Use of visual analog scales in economic evaluationExpert Review of Pharmacoeconomics & Outcomes Research, 2003